The DOI matches its Crossref record; 197 of the 197 references it cites were found in a registry or an index.
Drug development from marine natural products
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Natural products as sources of new drugs over the last 25 years
Newman, D. J., & Cragg, G. M. (2007) · Journal of Natural Products · doi:10.1021/np068054v · Cited by 5,517
The evolving role of natural products in drug discovery
Koehn, F. E., & Carter, G. T. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1657 · Cited by 2,572
Feling, R. H., Buchanan, G. O., Mincer, T. J., Kauffman, C. A., Jensen, P. R., & Fenical, W. (2003) · Angewandte Chemie International Edition · doi:10.1002/anie.200390115 · Cited by 1,057
Feher, M., & Schmidt, J. M. (2003) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci0200467 · Cited by 927
Conus Venoms: A Rich Source of Novel Ion Channel-Targeted Peptides
TERLAU, H., & OLIVERA, B. M. (2004) · Physiological Reviews · doi:10.1152/physrev.00020.2003 · Cited by 897
Targeting the Cell Cycle: A New Approach to Cancer Therapy
Schwartz, G. K., & Shah, M. A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.5594 · Cited by 817
Marine Natural Products and Related Compounds in Clinical and Advanced Preclinical Trials
Newman, D. J., & Cragg, G. M. (2004) · Journal of Natural Products · doi:10.1021/np040031y · Cited by 759
Peptide Neurotoxins from Fish-Hunting Cone Snails
Olivera, B. M., Gray, W. R., Zeikus, R., McIntosh, J. M., Varga, J., Rivier, J., de Santos, V., & Cruz, L. J. (1985) · Science · doi:10.1126/science.4071055 · Cited by 747
CALCIUM CHANNEL DIVERSITY AND NEUROTRANSMITTER RELEASE: The ω-Conotoxins and ω-Agatoxins
Olivera, B. M., Miljanich, G. P., Ramachandran, J., & Adams, M. E. (1994) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.63.070194.004135 · Cited by 734
Chauhan, D., Catley, L., Li, G., Podar, K., Hideshima, T., Velankar, M., Mitsiades, C., Mitsiades, N., Yasui, H., Letai, A., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.10.013 · Cited by 694
Isolation and structure of bryostatin 1
Pettit, G. R., Herald, C. L., Doubek, D. L., Herald, D. L., Arnold, E., & Clardy, J. (1982) · Journal of the American Chemical Society · doi:10.1021/ja00388a092 · Cited by 653
Anticancer Agents from Natural Products
(2005) · CRC Press eBooks · doi:10.1201/9781420039658 · Cited by 638
Ziconotide: Neuronal Calcium Channel Blocker for Treating Severe Chronic Pain
Miljanich, G. P. (2004) · Current Medicinal Chemistry · doi:10.2174/0929867043363884 · Cited by 607
The isolation and structure of a remarkable marine animal antineoplastic constituent: dolastatin 10
Pettit, G. R., Kamano, Y., Herald, C. L., Tuinman, A. A., Boettner, F. E., Kizu, H., Schmidt, J. M., Baczynskyj, L., Tomer, K. B., & Bontems, R. J. (1987) · Journal of the American Chemical Society · doi:10.1021/ja00256a070 · Cited by 583
Udwary, D. W., Zeigler, L., Asolkar, R. N., Singan, V., Lapidus, A., Fenical, W., Jensen, P. R., & Moore, B. S. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0700962104 · Cited by 536
Halichondrins-antitumor polyether macrolides from a marine sponge
Hirata, Y., & Uemura, D. (1986) · Pure and Applied Chemistry · doi:10.1351/pac198658050701 · Cited by 519
Gasser, T. C. (1992) · Fortschritte der Urologie und Nephrologie · doi:10.1007/978-3-642-85422-4_3 · Cited by 493
Rinehart, K. L., Holt, T. G., Fregeau, N. L., Stroh, J. G., Keifer, P. A., Sun, F., Li, L. H., & Martin, D. G. (1990) · The Journal of Organic Chemistry · doi:10.1021/jo00302a007 · Cited by 492
Towle, M. J., Salvato, K. A., Budrow, J., Wels, B. F., Kuznetsov, G., Aalfs, K. K., Welsh, S., Zheng, W., Seletsky, B. M., Palme, M. H., et al. (2001) · PubMed · Cited by 483
Costantino, L., & Barlocco, D. (2006) · PubMed · Cited by 411
Bergmann (1951) · doi:10.1021/jo01146a023 · Cited by 403
Total synthesis of halichondrin B and norhalichondrin B
Aicher, T. D., Buszek, K. R., Fang, F. G., Forsyth, C. J., Jung, S. H., Kishi, Y., Matelich, M. C., Scola, P. M., Spero, D. M., & Yoon, S. K. (1992) · Journal of the American Chemical Society · doi:10.1021/ja00034a086 · Cited by 400
Discodermolide, A Cytotoxic Marine Agent That Stabilizes Microtubules More Potently Than Taxol,
ter Haar, E., Kowalski, R. J., Hamel, E., Lin, C. M., Longley, R. E., Gunasekera, S. P., Rosenkranz, H. S., & Day, B. W. (1996) · Biochemistry · doi:10.1021/bi9515127 · Cited by 382
Bai, R. L., Paull, K. D., Herald, C. L., Malspeis, L., Pettit, G. R., & Hamel, E. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)98491-7 · Cited by 379
Gunasekera, S. P., Gunasekera, M., Longley, R. E., & Schulte, G. K. (1990) · The Journal of Organic Chemistry · doi:10.1021/jo00303a029 · Cited by 375
The discovery and development of marine compounds with pharmaceutical potential
Munro, M. H. G., Blunt, J. W., Dumdei, E. J., Hickford, S. J. H., Lill, R. E., Li, S., Battershill, C. N., & Duckworth, A. R. (1999) · Journal of Biotechnology · doi:10.1016/s0168-1656(99)00052-8 · Cited by 369
Enantioselective Total Synthesis of Ecteinascidin 743
Corey, E. J., Gin, D. Y., & Kania, R. S. (1996) · Journal of the American Chemical Society · doi:10.1021/ja962480t · Cited by 352
Takebayashi, Y., Pourquier, P., Zimonjic, D. B., Nakayama, K., Emmert, S., Ueda, T., Urasaki, Y., Kanzaki, A., Akiyama, S.-I., Popescu, N., et al. (2001) · Nature Medicine · doi:10.1038/91008 · Cited by 348
Dolastatin 10, a powerful cytostatic peptide derived from a marine animal
Bai, R., Petit, G. R., & Hamel, E. (1990) · Biochemical Pharmacology · doi:10.1016/0006-2952(90)90613-p · Cited by 321
Maldonado, L. A., Fenical, W., Jensen, P. R., Kauffman, C. A., Mincer, T. J., Ward, A. C., Bull, A. T., & Goodfellow, M. (2005) · International Journal of Systematic and Evolutionary Microbiology · doi:10.1099/ijs.0.63625-0 · Cited by 317
Pharmaceuticals from cultured algae
Schwartz, R. E., Hirsch, C. F., Sesin, D. F., Flor, J. E., Chartrain, M., Fromtling, R. E., Harris, G. H., Salvatore, M. J., Liesch, J. M., & Yudin, K. (1990) · Journal of Industrial Microbiology · doi:10.1007/bf01573860 · Cited by 314
Sudek, S., Lopanik, N. B., Waggoner, L. E., Hildebrand, M., Anderson, C., Liu, H., Patel, A., Sherman, D. H., & Haygood, M. G. (2007) · Journal of Natural Products · doi:10.1021/np060361d · Cited by 314
Phase II Study of Ecteinascidin-743 in Advanced Pretreated Soft Tissue Sarcoma Patients
Yovine, A., Riofrio, M., Blay, J. Y., Brain, E., Alexandre, J., Kahatt, C., Taamma, A., Jimeno, J., Martin, C., Salhi, Y., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.210 · Cited by 310
Didemnins: Antiviral and Antitumor Depsipeptides from a Caribbean Tunicate
Rinehart, K. L., Gloer, J. B., Hughes, R. G., Renis, H. E., McGovren, J. P., Swynenberg, E. B., Stringfellow, D. A., Kuentzel, S. L., & Li, L. H. (1981) · Science · doi:10.1126/science.7233187 · Cited by 308
Trimurtulu, G., Ohtani, I., Patterson, G. M. L., Moore, R. E., Corbett, T. H., Valeriote, F. A., & Demchik, L. (1994) · Journal of the American Chemical Society · doi:10.1021/ja00090a020 · Cited by 303
Pommier, Y., Kohlhagen, G., Bailly, C., Waring, M., Mazumder, A., & Kohn, K. W. (1996) · Biochemistry · doi:10.1021/bi960306b · Cited by 303
Discovery and development of the anticancer agent salinosporamide A (NPI-0052)
Fenical, W., Jensen, P. R., Palladino, M. A., Lam, K. S., Lloyd, G. K., & Potts, B. C. (2009) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2008.10.075 · Cited by 291
Norhalichondrin A: an antitumor polyether macrolide from a marine sponge
Uemura, D., Takahashi, K., Yamamoto, T., Katayama, C., Tanaka, J., Okumura, Y., & Hirata, Y. (1985) · Journal of the American Chemical Society · doi:10.1021/ja00302a042 · Cited by 289
Phorboxazoles A and B: potent cytostatic macrolides from marine sponge Phorbas species
Searle, P. A., & Molinski, T. F. (1995) · Journal of the American Chemical Society · doi:10.1021/ja00136a009 · Cited by 288
Self-citationBai, R. L., Pettit, G. R., & Hamel, E. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)44880-0 · Cited by 286
Synthesis of Ecteinascidin ET-743 and Phthalascidin Pt-650 from Cyanosafracin B
Cuevas, C., Pérez, M., Martín, M. J., Chicharro, J. L., Fernández-Rivas, C., Flores, M., Francesch, A., Gallego, P., Zarzuelo, M., de la Calle, F., et al. (2000) · Organic Letters · doi:10.1021/ol0062502 · Cited by 282
Naturally Occurring and Synthetic Imidazoles: Their Chemistry and Their Biological Activities
Luca, L. (2006) · Current Medicinal Chemistry · doi:10.2174/0929867310607010001 · Cited by 279
Bowersox, S. S., Gadbois, T., Singh, T., Pettus, M., Wang, Y. X., & Luther, R. R. (1996) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)21283-6 · Cited by 274
Antitumor tetrahydroisoquinoline alkaloids from the colonial ascidian Ecteinascidia turbinata
Wright, A. E., Forleo, D. A., Gunawardana, G. P., Gunasekera, S. P., Koehn, F. E., & McConnell, O. J. (1990) · The Journal of Organic Chemistry · doi:10.1021/jo00302a006 · Cited by 268
Kowalski, R. J., Giannakakou, P., Gunasekera, S. P., Longley, R. E., Day, B. W., & Hamel, E. (1997) · Molecular Pharmacology · doi:10.1124/mol.52.4.613 · Cited by 262
Structures of the didemnins, antiviral and cytotoxic depsipeptides from a Caribbean tunicate
Rinehart, K. L., Gloer, J. B., Cook, J. C., Mizsak, S. A., & Scahill, T. A. (1981) · Journal of the American Chemical Society · doi:10.1021/ja00397a055 · Cited by 256
Total Synthesis of Bryostatin 2
Evans, D. A., Carter, P. H., Carreira, E. M., Charette, A. B., Prunet, J. A., & Lautens, M. (1999) · Journal of the American Chemical Society · doi:10.1021/ja990860j · Cited by 254
Hamann, M. T., Otto, C. S., Scheuer, P. J., & Dunbar, D. C. (1996) · The Journal of Organic Chemistry · doi:10.1021/jo960877+ · Cited by 240
Hamann, M. T., & Scheuer, P. J. (1993) · Journal of the American Chemical Society · doi:10.1021/ja00066a061 · Cited by 237
Kageyama, M., Tamura, T., Nantz, M. H., Roberts, J. C., Somfai, P., Whritenour, D. C., & Masamune, S. (1990) · Journal of the American Chemical Society · doi:10.1021/ja00176a058 · Cited by 230
Hennings, H., Blumberg, P. M., Pettit, G. R., Herald, C. L., Shores, R., & Yuspa, S. H. (1987) · Carcinogenesis · doi:10.1093/carcin/8.9.1343 · Cited by 230
Ecteinascidin 743: A Minor Groove Alkylator That Bends DNA toward the Major Groove
Zewail-Foote, M., & Hurley, L. H. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm990241l · Cited by 214
Differential mitotic responses to microtubule-stabilizing and -destabilizing drugs.
Chen, J.-G., & Horwitz, S. B. (2002) · PubMed · Cited by 212
Ruggieri, G. D. (1976) · Science · doi:10.1126/science.9691 · Cited by 209
Modeling of the bryostatins to the phorbol ester pharmacophore on protein kinase C.
Wender, P. A., Cribbs, C. M., Koehler, K. F., Sharkey, N. A., Herald, C. L., Kamano, Y., Pettit, G. R., & Blumberg, P. M. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.19.7197 · Cited by 201
Pettit, G. R., Herald, C. L., Boyd, M. R., Leet, J. E., Dufresne, C., Doubek, D. L., Schmidt, J. M., Cerny, R. L., Hooper, J. N. A., & Rutzler, K. C. (1991) · Journal of Medicinal Chemistry · doi:10.1021/jm00115a027 · Cited by 191
Suárez, Y., González, L. E., Cuadrado, A., Berciano, M., Lafarga, M., & Múñoz, A. (2003) · PubMed · Cited by 191
Chauhan, D., Singh, A., Brahmandam, M., Podar, K., Hideshima, T., Richardson, P., Munshi, N., Palladino, M. A., & Anderson, K. C. (2008) · Blood · doi:10.1182/blood-2007-08-105601 · Cited by 190
Escuin, D., Kline, E. R., & Giannakakou, P. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4095 · Cited by 183
Chemistry and clinical biology of the bryostatins
Mutter, R., & Wills, M. (2000) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(00)00150-4 · Cited by 178
Pettit, G. R., Singh, S. B., Hogan, F., Lloyd-Williams, P., Herald, D. L., Burkett, D. D., & Clewlow, P. J. (1989) · Journal of the American Chemical Society · doi:10.1021/ja00196a061 · Cited by 177
Total Synthesis of Cryptophycins. Revision of the Structures of Cryptophycins A and C
Barrow, R. A., Hemscheidt, T., Liang, J., Paik, S., Moore, R. E., & Tius, M. A. (1995) · Journal of the American Chemical Society · doi:10.1021/ja00114a011 · Cited by 168
Total Synthesis of Bryostatin 3
Ohmori, K., Ogawa, Y., Obitsu, T., Ishikawa, Y., Nishiyama, S., & Yamamura, S. (2000) · Angewandte Chemie International Edition · Cited by 168
Sakai, R., Rinehart, K. L., Guan, Y., & Wang, A. H. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.23.11456 · Cited by 167
Taxol and discodermolide represent a synergistic drug combination in human carcinoma cell lines.
Martello, L. A., McDaid, H. M., Regl, D. L., Yang, C. P., Meng, D., Pettus, T. R. R., Kaufman, M. D., Arimoto, H., Danishefsky, S. J., Smith, A. B., et al. (2000) · PubMed · Cited by 166
Trabectedin for Women With Ovarian Carcinoma After Treatment With Platinum and Taxanes Fails
Sessa, C., De Braud, F., Perotti, A., Bauer, J., Curigliano, G., Noberasco, C., Zanaboni, F., Gianni, L., Marsoni, S., Jimeno, J., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.032 · Cited by 162
Anderson, H. J., Coleman, J. E., Andersen, R. J., & Roberge, M. (1996) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050564 · Cited by 160
Cytotoxic peptides from the marine sponge Cymbastela sp.
Coleman, J. E., de Silva, E. D., Kong, F., et al. (1995) · Tetrahedron · doi:10.1016/0040-4020(95)00646-p · Cited by 157
Cuadrado, A., García‐Fernández, L., González, L., Suárez, Y., Losada, A., Alcaide, V., Martı́nez, T., Fernández-Sousa, J. M., Sánchez-Puelles, J.-M., & Múñoz, A. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m201010200 · Cited by 157
Arenastatin A, a potent cytotoxic depsipeptide from the Okinawan marine sponge Dysidea arenaria
Kobayashi, M., Aoki, S., Ohyabu, N., Kurosu, M., Wang, W., & Kitagawa, I. (1994) · Tetrahedron Letters · doi:10.1016/s0040-4039(00)78398-5 · Cited by 155
Natural products as probes of cell biology: 20 years of didemnin research
Vera, M. D., & Joullié, M. M. (2002) · Medicinal Research Reviews · doi:10.1002/med.10003 · Cited by 154
Broggini, M., Marchini, S., Galliera, E., Borsotti, P., Taraboletti, G., Erba, E., Sironi, M., Jimeno, J. M., Faircloth, G. T., Giavazzi, R., et al. (2003) · Leukemia · doi:10.1038/sj.leu.2402788 · Cited by 151
Piel, J. (2005) · Current Medicinal Chemistry · doi:10.2174/092986706775197944 · Cited by 147
Total synthesis of the immunosuppressive agent (-)-discodermolide
Nerenberg, J. B., Hung, D. T., Somers, P. K., & Schreiber, S. L. (1993) · Journal of the American Chemical Society · doi:10.1021/ja00079a066 · Cited by 145
New drugs from marine microbes: The tide is turning
Newman, D. J., & Hill, R. T. (2006) · Journal of Industrial Microbiology & Biotechnology · doi:10.1007/s10295-006-0115-2 · Cited by 144
Urdiales, J. L., Morata, P., de Castro, I. N., & Sánchez‐Jiménez, F. (1996) · Cancer Letters · doi:10.1016/0304-3835(96)04151-1 · Cited by 142
Synthesis and Structure Determination of Kahalalide F1,2
López-Macià, À., Jiménez, J. C., Royo, M., et al. (2001) · Journal of the American Chemical Society · doi:10.1021/ja0116728 · Cited by 141
Hung, D. T., Chen, J., & Schreiber, S. L. (1996) · Chemistry & Biology · doi:10.1016/s1074-5521(96)90108-8 · Cited by 141
GTP-dependent binding of the antiproliferative agent didemnin to elongation factor 1 alpha.
Crews, C. M., Collins, J. L., Lane, W. S., Snapper, M. L., & Schreiber, S. L. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)40692-2 · Cited by 140
Hildebrand, M., Waggoner, L. E., Liu, H., Sudek, S., Allen, S. W., Bassis, C. M., Sherman, D. H., & Haygood, M. G. (2004) · Chemistry & Biology · doi:10.1016/j.chembiol.2004.08.018 · Cited by 138
Loganzo, F., Discafani, C. M., Annable, T., Beyer, C. F., Musto, S., Hari, M., Tan, X., Hardy, C., Hernandez, R., Baxter, M., et al. (2003) · PubMed · Cited by 137
García‐Fernández, L., Losada, A., Alcaide, V., Alvarez, A. M., Cuadrado, A., González, L. E., Nakayama, K., Nakayama, K., Fernandez-Sousa, J. M., Múñoz, A., et al. (2002) · Oncogene · doi:10.1038/sj.onc.1205972 · Cited by 136
Vaishampayan, U. N., Glodé, M., Du, W., Kraft, A. S., Hudes, G. R., Wright, J. D., & Hussain, M. (2000) · PubMed · Cited by 136
Dolastatin 15, a potent antimitotic depsipeptide derived from Dolabella auricularia
Bai, R., Friedman, S., Pettit, G. R., et al. (1992) · Biochemical Pharmacology · doi:10.1016/0006-2952(92)90153-a · Cited by 129
Ecteinascidin 743: a novel anticancer drug with a unique mechanism of action
Aune, G. J., Furuta, T., & Pommier, Y. G. (2002) · Anti-Cancer Drugs · doi:10.1097/00001813-200207000-00001 · Cited by 129
Janmaat, M. L., Rodríguez, J. A., Jimeno, J. M., Kruyt, F. A. E., & Giaccone, G. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.011361 · Cited by 123
Gram-Scale Synthesis of (+)-Discodermolide
Smith, A. B., Kaufman, M. D., Beauchamp, T. J., LaMarche, M. J., & Arimoto, H. (1999) · Organic Letters · doi:10.1021/ol9910870 · Cited by 120
Dabydeen, D. A., Burnett, J. C., Bai, R., Verdier‐Pinard, P., Hickford, S. J. H., Pettit, G. R., Blunt, J. W., Munro, M. H. G., Gussio, R., & Hamel, E. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.026641 · Cited by 119
Bowersox, S. S., & Luther, R. R. (1998) · Toxicon · doi:10.1016/s0041-0101(98)00158-5 · Cited by 117
Gohil, K., BELL, J. R., Ramachandran, J., & Miljanich, G. P. (1994) · Brain Research · doi:10.1016/0006-8993(94)90398-0 · Cited by 116
Synthesis of bryostatins. 1. Construction of the C(1)-C(16) fragment
Blanchette, M. A., Malamas, M. S., Nantz, M. H., Roberts, J. C. Q., Somfai, P., Whritenour, D. C., Masamune, S., Kageyama, M., & Tamura, T. (1989) · The Journal of Organic Chemistry · doi:10.1021/jo00273a009 · Cited by 112
Pettit, G. R., Tan, R., Gao, F., et al. (1993) · The Journal of Organic Chemistry · doi:10.1021/jo00061a030 · Cited by 112
Edelman, M. J. (2003) · Lung Cancer · doi:10.1016/s0169-5002(02)00511-1 · Cited by 109
Food-drugs from the sea : proceedings
Youngken, H. W., & Worthen, L. R. (1970) · Medical Entomology and Zoology · Cited by 108
Synthesis of the First Members of a New Class of Biologically Active Bryostatin Analogues
Wender, P. A., Brabander, J. K. D., Harran, P. G., Jimenez, J., Koehler, M. F. T., Lippa, B., Park, C., & Shiozaki, M. (1998) · Journal of the American Chemical Society · doi:10.1021/ja9727631 · Cited by 105
The Microtubule Stabilizing Agent Discodermolide is a Potent Inducer of Accelerated Cell Senescence
Klein, L. E., Freeze, B. S., Smith, A. B., & Horwitz, S. B. (2005) · Cell Cycle · doi:10.4161/cc.4.3.1550 · Cited by 104
DISCODERMOLIDE—A NEW, MARINE-DERIVED IMMUNOSUPPRESSIVE COMPOUND: I. IN VITRO STUDIES
LONGLEY, R. E., CADDIGAN, D., HARMODY, D., GUNASEKERA, M., & GUNASEKERA, S. P. (1991) · Transplantation · doi:10.1097/00007890-199110000-00014 · Cited by 104
CONTRIBUTIONS TO THE STUDY OF MARINE PRODUCTS
Bergmann, W. (1937) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)74505-5 · Cited by 103
Antitumor Activity of TZT‐1027, a Novel Doiastatin 10 Derivative
Kobayashi, M., Natsume, T., Tamaoki, S., Watanabe, J., Asano, H., Mikami, T., Miyasaka, K., Miyazaki, K., Gondo, M., SAKAKIBARA, K., et al. (1997) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1997.tb00383.x · Cited by 103
The antitumoral compound Kahalalide F acts on cell lysosomes
Garcı́a-Rocha, M., Bonay, P., & Ávila, J. (1996) · Cancer Letters · doi:10.1016/0304-3835(95)04036-6 · Cited by 103
Phase II trial of dolastatin-10 in patients with advanced breast cancer
Perez, E. A., Hillman, D. W., Fishkin, P. A. S., Krook, J. E., Tan, W. W., Kuriakose, P., Alberts, S. R., & Dakhil, S. R. (2005) · Investigational New Drugs · doi:10.1007/s10637-005-6735-y · Cited by 102
Mechanism of Action of Cryptophycin
Smith, C. D., & Zhang, X. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.11.6192 · Cited by 101
Phase I trial of dolastatin-10 (NSC 376128) in patients with advanced solid tumors.
Pitot, H. C., McElroy, E., Reid, J. M., Windebank, A. J., Sloan, J. A., Erlichman, C., Bagniewski, P. G., Walker, D. L., Rubin, J., Goldberg, R. M., et al. (1999) · PubMed · Cited by 101
Honoré, S., Kamath, K., Braguer, D., Horwitz, S. B., Wilson, L., Briand, C. M., & Jordan, M. A. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0693 · Cited by 100
Cytotoxic and tubulin-interactive hemiasterlins from Auletta sp. and Siphonochalina spp. sponges
Gamble, W. R., Durso, N. A., Fuller, R. W., Westergaard, C. K., Johnson, T. R., Sackett, D. L., Hamel, E., Cardellina, J. H., & Boyd, M. R. (1999) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(99)00089-9 · Cited by 98
Chun, H. G., Davies, B., Hoth, D. F., Suffness, M., Plowman, J., Flora, K. P., Grieshaber, C. K., & Leyland-Jones, B. R. (1986) · Investigational New Drugs · doi:10.1007/bf00179597 · Cited by 98
Varterasian, M. L., Mohammad, R. M., Shurafa, M. S., Hulburd, K., Pemberton, P., Rodriguez, D. H., Spadoni, V., Eilender, D. S., Murgo, A. J., Wall, N. R., et al. (2000) · PubMed · Cited by 97
Takahashi, N., Li, W. W., Banerjee, D., Scotto, K. W., & Bertino, J. R. (2001) · PubMed · Cited by 96
Isakov, N., Galron, D., Mustelin, T., Pettit, G. R., & Altman, A. (1993) · The Journal of Immunology · doi:10.4049/jimmunol.150.4.1195 · Cited by 92
Madden, T. L., Tran, H. T., Beck, D., Huie, R., Newman, R. A., Pusztai, L., Wright, J. R., & Abbruzzese, J. L. (2000) · PubMed · Cited by 90
Mechanism of Action of the Unusually Potent Microtubule Inhibitor Cryptophycin 1
Panda, D., Himes, R. H., Moore, R. E., Wilson, L., & Jordan, M. A. (1997) · Biochemistry · doi:10.1021/bi971302p · Cited by 89
Progress in the clinical development of new marine-derived anticancer compounds
Jimeno, J. M., Lopez-Martin, J. A., Ruiz‐Casado, A., Izquierdo, M. A., Scheuer, P. J., & RINEHART, K. L. J. (2004) · Anti-Cancer Drugs · doi:10.1097/00001813-200404000-00003 · Cited by 88
Contributions to the Study of Marine Products. XL. The Nucleosides of Sponges.1 IV. Spongosine2
Bergmann, W., & BURKE, D. C. (1956) · The Journal of Organic Chemistry · doi:10.1021/jo01108a020 · Cited by 88
Bai, R., Durso, N. A., Sackett, D. L., & Hamel, E. (1999) · Biochemistry · doi:10.1021/bi991323e · Cited by 87
Antiangiogenic activity of aplidine, a new agent of marine origin
Taraboletti, G., Poli, M., Dossi, R., Manenti, L., Borsotti, P., Faircloth, G. T., Broggini, M., D’Incalci, M., Ribatti, D., & Giavazzi, R. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601864 · Cited by 87
In vitro pharmacology of cryptophycin 52 (LY355703) in human tumor cell lines
Wagner, M. M. F., Paul, D. C., Shih, C., Jordan, M. A., Wilson, L., & Williams, D. C. (1999) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050871 · Cited by 87
Rademaker-Lakhai, J. M., Horenblas, S., MEINHARDT, W., Stokvis, E., de Reijke, T. M., Jimeno, J. M., Lázaro, L. L., Lopez-Martin, J. A., Beijnen, J. H., & Schellens, J. H. M. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1534 · Cited by 87
ChemInform Abstract: ISOLATION AND STRUCTURE OF BRYOSTATIN 1
Pettit, G. R., Herald, C. L., Doubek, D. L., Herald, D. L., Arnold, E., & Clardy, J. (1983) · ChemInform · doi:10.1002/chin.198309065 · Cited by 87
Zelek, L. H., Yovine, A. J., Brain, E. G. C., Turpin, F., Taamma, A., Riofrio, M., Spielmann, M., Jimeno, J. M., & Misset, J. L. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603142 · Cited by 86
A phase II study of bryostatin 1 in metastatic malignant melanoma
Propper, D., Macaulay, V. M., O'Byrne, K. J., Braybrooke, J. P., Wilner, S., Ganesan, T., Talbot, D., & Harris, A. L. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.680 · Cited by 83
Margolin, K. A., Longmate, J., Synold, T. W., Gandara, D. R., Weber, J. S., Gonzalez, R. C., Johansen, M. J., Newman, R. A., Baratta, T., & Doroshow, J. H. (2001) · Investigational New Drugs · doi:10.1023/a:1010626230081 · Cited by 82
The clinical development of the bryostatins
Clamp, A. R., & Jayson, G. C. (2002) · Anti-Cancer Drugs · doi:10.1097/00001813-200208000-00001 · Cited by 82
A phase II trial of bryostatin 1 in the treatment of metastatic colorectal cancer.
Zonder, J. A., Shields, A. F., Zalupski, M. M., Chaplen, R., Heilbrun, L. K., Arlauskas, P., & Philip, P. A. (2001) · PubMed · Cited by 82
Zewail‐Foote, M., LI, V. ‐., Kohn, H., Bearss, D. J., Guzman, M., & Hurley, L. H. (2001) · Chemistry & Biology · doi:10.1016/s1074-5521(01)00071-0 · Cited by 79
Effective combination of ET-743 and doxorubicin in sarcoma: preclinical studies
Riccardi, R., Meco, D., Colombo, T., Ubezio, P., Zucchetti, M., Zaffaroni, M., Riccardi, A., Faircloth, G. T., Jose, J., & D’Incalci, M. (2003) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-003-0636-6 · Cited by 77
Interaction of cryptophycin 1 with tubulin and microtubules
Kerksiek, K. M., Mejillano, M. R., Schwartz, R. E., Georg, G. I., & Himes, R. H. (1995) · FEBS Letters · doi:10.1016/0014-5793(95)01271-0 · Cited by 75
Liang, J., Moore, R. E., Moher, E. D., MUNROE, J. E., Al‐awar, R., Hay, D. A., Varie, D. L., Zhang, T. Y., Aikins, J. A., Martinelli, M. J., et al. (2005) · Investigational New Drugs · doi:10.1007/s10637-005-6729-9 · Cited by 75
Chemical Defenses of the Sacoglossan Mollusk Elysia rufescens and Its Host Alga Bryopsis sp.
Becerro, M. A., Goetz, G. H., Paul, V. J., et al. (2001) · Journal of Chemical Ecology · doi:10.1023/a:1012287105923 · Cited by 74
Paterson, I., Delgado, Ó., Florence, G. J., Lyothier, I., O’Brien, M., Scott, J. P., & Sereinig, N. (2004) · The Journal of Organic Chemistry · doi:10.1021/jo048534w · Cited by 73
Gajate, C., An, F., & Mollinedo, F. (2003) · PubMed · Cited by 72
Pharmaceutical development of anticancer agents derived from marine sources
Nuijen, B., Bouma, M., Manada, C., Jimeno, J. M., Schellens, J. H. M., Bult, A., & Beijnen, J. H. (2000) · Anti-Cancer Drugs · doi:10.1097/00001813-200011000-00003 · Cited by 71
DISCODERMOLIDE—A NEW, MARINE-DERIVED IMMUNOSUPPRESSIVE COMPOUND
Longley, R. E., CADDIGAN, D., Harmody, D. K., Gunasekera, M., & Gunasekera, S. P. (1991) · Transplantation · doi:10.1097/00007890-199110000-00015 · Cited by 71
Cytotoxicity and neurocytotoxicity of new marine anticancer agents evaluated using in vitro assays
Geldof, A. A., Mastbergen, S. C., Henrar, R. E. C., & Faircloth, G. T. (1999) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050983 · Cited by 70
Localization of the Antimitotic Peptide and Depsipeptide Binding Site on β-Tubulin
Mitra, A., & Sept, D. (2004) · Biochemistry · doi:10.1021/bi0487387 · Cited by 67
JNK activation is critical for Aplidin™-induced apoptosis
Cuadrado, A., González, L., Suárez, Y., Martínez, T., & Múñoz, A. (2004) · Oncogene · doi:10.1038/sj.onc.1207636 · Cited by 66
Phase II study of dolastatin-10 in patients with advanced non-small-cell lung cancer
Krug, L. M., Miller, V. A., Kalemkerian, G. P., Kraut, M., Ng, K., Heelan, R. T., Pizzo, B. A., Perez, W., McClean, N., & Kris, M. G. (2000) · Annals of Oncology · doi:10.1023/a:1008349209956 · Cited by 66
Ajani, J. A., Jiang, Y., Faust, J., Chang, B. B., Ho, L., Yao, J. C., Rousey, S. R., Dakhil, S. R., Cherny, R. C., Craig, C. M., et al. (2006) · Investigational New Drugs · doi:10.1007/s10637-006-6452-1 · Cited by 65
Poruchynsky, M. S., Kim, J.-H., Nogales, E., Annable, T., Loganzo, F., Greenberger, L. M., Sackett, D. L., & Fojo, T. (2004) · Biochemistry · doi:10.1021/bi049300+ · Cited by 65
Donald, S., Verschoyle, R. D., Greaves, P., Gant, T. W., Colombo, T., Zaffaroni, M., Frapolli, R., Zucchetti, M., D’Incalci, M., Meco, D., et al. (2003) · PubMed · Cited by 64
Phase II Study of Dolastatin-10 as First-Line Treatment for Advanced Colorectal Cancer
Saad, E. D., Kraut, E. H., Hoff, P. M., Moore, D. F., Jones, D., Pazdur, R., & Abbruzzese, J. L. (2002) · American Journal of Clinical Oncology · doi:10.1097/00000421-200210000-00005 · Cited by 64
Phase II trials of dolastatin-10 in advanced pancreaticobiliary cancers
Kindler, H. L., Tothy, P. K., Wolff, R. A., McCormack, R. A., Abbruzzese, J. L., Mani, S., Wade-Oliver, K. T., & Vokes, E. E. (2005) · Investigational New Drugs · doi:10.1007/s10637-005-2909-x · Cited by 62
Structure–activity relationships of Halichondrin B analogues: modifications at C.30–C.38
Wang, Y., Habgood, G. J., Christ, W. J., Kishi, Y., Littlefield, B. A., & Yu, M. J. (2000) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(00)00150-5 · Cited by 61
Cell cycle phase perturbations and apoptosis in tumour cells induced by aplidine
Erba, E., Bassano, L., Liberti, G., Muradore, I., Chiorino, G., Ubezio, P., Vignati, S., Codegoni, A. M., Desiderio, M. A., Faircloth, G. T., et al. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600265 · Cited by 61
Honoré, S., Kamath, K., Braguer, D., Wilson, L., Briand, C. M., & Jordan, M. A. (2003) · PubMed · Cited by 61
Characterization of the Interaction of TZT‐1027, a Potent Antitumor Agent, with Tubulin
Natsume, T., Watanabe, J., Tamaoki, S., Fujio, N., Miyasaka, K., & Kobayashi, M. (2000) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.2000.tb01007.x · Cited by 58
A Steroid Derivative with Paclitaxel-Like Effects on Tubulin Polymerization
Verdier‐Pinard, P., Wang, Z., Mohanakrishnan, A. K., Cushman, M., & Hamel, E. (2000) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)26423-3 · Cited by 58
The mechanism of action of Kahalalide F: Variable cell permeability in human hepatoma cell lines
Sewell, J. M., Mayer, I., Langdon, S. P., Smyth, J. F., Jodrell, D. I., & Guichard, S. M. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.04.015 · Cited by 56
Immunosuppression by Discodermolide
Longley, R. E., Gunasekera, S. P., Faherty, D. A., McLane, J. A., & Dumont, F. J. (1993) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1993.tb17145.x · Cited by 54
Roles of Individual Disulfide Bonds in the Stability and Folding of an ω-Conotoxin
Price-Carter, M. L., Hull, M. S., & Goldenberg, D. P. (1998) · Biochemistry · doi:10.1021/bi9803978 · Cited by 54
Bergmann, W., & Stempien, M. F. (1957) · The Journal of Organic Chemistry · doi:10.1021/jo01363a009 · Cited by 53
Didemnin B Induces Cell Death by Apoptosis: The Fastest Induction of Apoptosis Ever Described
Grubb, D. R., Wolvetang, E. J., & Lawen, A. (1995) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1995.2580 · Cited by 53
Stereochemistry of Kahalalide F
Bonnard, I., Manzanares, I., & RINEHART, K. L. J. (2003) · Journal of Natural Products · doi:10.1021/np030334c · Cited by 53
Effect of Aplidin in acute lymphoblastic leukaemia cells
Erba, E., Serafini, M., Gaipa, G., Tognon, G., Marchini, S., Celli, N., Rotilio, D., Broggini, M., Jimeno, J. M., Faircloth, G. T., et al. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601130 · Cited by 53
Inhibition of Protein Synthesis by Didemnin B: How EF-1α Mediates Inhibition of Translocation
Ahuja, D., Vera, M. D., SirDeshpande, B. V., et al. (2000) · Biochemistry · doi:10.1021/bi992202h · Cited by 51
Blay, J., Cesne, A. L., Verweij, J., Scurr, M. R., Seynaeve, C., Bonvalot, S., Hogendoorn, P. C. W., Jimeno, J. M., Evrard, V., Glabbeke, M. M. V., et al. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2004.02.005 · Cited by 51
Phase Ib trial of bryostatin 1 in patients with refractory malignancies.
Grant, S., Roberts, J. D., Poplin, E. A., Tombes, M. B., Kyle, B., Welch, D. G., Carr, M. A., & Bear, H. D. (1998) · PubMed · Cited by 51
Shin, D. M., Holoye, P. Y., Murphy, W. K., Forman, A. D., & Papasozomenos, S. C. (1991) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00687325 · Cited by 50
A Phase II trial of bryostatin-1 for patients with metastatic renal cell carcinoma
Pagliaro, L. C., Daliani, D., Amato, R. J., Tu, S., JONES, D. M., Smith, T., Logothetis, C. J., & Millikan, R. E. (2000) · Cancer · doi:10.1002/1097-0142(20000801)89:3<615::aid-cncr17>3.0.co;2-j · Cited by 50
Skepper, C. K., MacMillan, J. B., Zhou, G.-X., Masuno, M. N., & Molinski, T. F. (2007) · Journal of the American Chemical Society · doi:10.1021/ja0703978 · Cited by 49
Self-citationSCIENCE/TECHNOLOGY: Supply Issues Complicate Trek Of Chemicals From Sea To Market
ROUHI, A. M. (1995) · Chemical & Engineering News · doi:10.1021/cen-v073n047.p042 · Cited by 49
Paterson, I., & Lyothier, I. (2004) · Organic Letters · doi:10.1021/ol0478842 · Cited by 47
Dowlati, A., Lazarus, H. M., Hartman, P. H., Jacobberger, J. W., Whitacre, C. M., Gerson, S. L., Ksenich, P., Cooper, B., Frisa, P. S., Gottlieb, M. A., et al. (2003) · PubMed · Cited by 46
Berkow, R. L., Schlabach, L., Dodson, R., Benjamin, W. H., Pettit, G. R., Rustagi, P. K., & Kraft, A. S. (1993) · PubMed · Cited by 45
Stevenson, J. P., Sun, W., Gallagher, M., Johnson, R., Vaughn, D. J., Schuchter, L. M., Algazy, K., Hahn, S. M., Enas, N. H., Ellis, D., et al. (2002) · PubMed · Cited by 44
Aquacultural Production of Bryostatin 1 and Ecteinascidin 743
Mendola, D. (2000) · KARGER eBooks · doi:10.1159/000062482 · Cited by 43
Phase II Study of Bryostatin 1 in Patients with Relapsed Multiple Myeloma
Varterasian, M. L., Pemberton, P., Hulburd, K., Rodriguez, D. H., Murgo, A. J., & Al-Katib, A. M. (2001) · Investigational New Drugs · doi:10.1023/a:1010676719178 · Cited by 42
Discodermolide interferes with the binding of tau protein to microtubules
Kar, S., Florence, G. J., Paterson, I., & Amos, L. (2003) · FEBS Letters · doi:10.1016/s0014-5793(03)00181-9 · Cited by 42
Distinct binding and cellular properties of synthetic (+)- and (-)-discodermolides
Hung, D. T., Nerenberg, J. B., & Schreiber, S. L. (1994) · Chemistry & Biology · doi:10.1016/1074-5521(94)90042-6 · Cited by 42
Hepatotoxicity and metabolism of trabectedin: a literature review
Beumer, J. H., Schellens, J. H. M., & Beijnen, J. H. (2005) · Pharmacological Research · doi:10.1016/j.phrs.2004.12.001 · Cited by 42
Modulation of gene expression in the acute promyelocytic leukemia cell line NB4.
Hu, Z., Ma, W., Uphoff, C. C., Lanotte, M., & Drexler, H. G. (1993) · PubMed · Cited by 41
Phase II evaluation of bryostatin-1 in metastatic melanoma
Bedikian, A. Y., Plager, C., Stewart, J. R., O'Brian, C. A., Herdman, S., Ross, M., Papadopoulos, N., Eton, O. E., Ellerhorst, J. A., & Smith, T. (2001) · Melanoma Research · doi:10.1097/00008390-200104000-00014 · Cited by 40
Grubb, D. R., Ly, J. D., Vaillant, F., Johnson, K. L., & Lawen, A. (2001) · Oncogene · doi:10.1038/sj.onc.1204545 · Cited by 40
Clamp, A. R., Blackhall, F. H., Vasey, P. A., Soukop, M., Coleman, R. E., Halbert, G., Robson, L., & Jayson, G. C. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601285 · Cited by 39
Phase II Trial of Dolastatin‐10, a Novel Anti‐Tubulin Agent, in Metastatic Soft Tissue Sarcomas
von Mehren, M., Balcerzak, S. P., Kraft, A. S., Edmonson, J. H., Okuno, S. H., Davey, M., McLaughlin, S. B., Beard, M., & Rogatko, A. (2004) · Sarcoma · doi:10.1155/2004/924913 · Cited by 39
Loganzo, F., Hari, M., Annable, T., Tan, X., Morilla, D. B., Musto, S., Zask, A., Kaplan, J. A., Minnick, A. A., May, M. K., et al. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1319.3.10 · Cited by 39
Brandon, E. F. A., Meijerman, I., Klijn, J. S., den Arend, D., Sparidans, R. W., Lázaro, L. L., Beijnen, J. H., & Schellens, J. H. M. (2005) · Anti-Cancer Drugs · doi:10.1097/01.cad.0000180121.16407.38 · Cited by 36
Sparidans, R. W., Stokvis, E., Jimeno, J. M., Lázaro, L. L., Schellens, J. H. M., & Beijnen, J. H. (2001) · Anti-Cancer Drugs · doi:10.1097/00001813-200108000-00003 · Cited by 36
Hickman, P. H., Kemp, G. J., Thompson, C., Salisbury, A., Wade, K., Harris, A. L., & Radda, G. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.449 · Cited by 35
Atkinson, R. A., Kieffer, B., Dejaegere, A. P., Sirockin, F., & Lefèvre, J. (2000) · Biochemistry · doi:10.1021/bi992651h · Cited by 35
Gómez, S. G., Bueren, J. A., Faircloth, G. T., Jimeno, J. M., & Albella, B. (2003) · Experimental Hematology · doi:10.1016/j.exphem.2003.07.004 · Cited by 35
Phase II clinical and pharmacological study of didemnin B in patients with metastatic breast cancer
Benvenuto, J. A., Newman, R. A., Bignami, G. S., Raybould, T. J. G., Raber, M. N., Esparza, L., & Walters, R. S. (1992) · Investigational New Drugs · doi:10.1007/bf00873128 · Cited by 35
Discodermolide analogues as the chemical component of combination bacteriolytic therapy
Smith, A. B., Freeze, B. S., LaMarche, M. J., Sager, J. A., Kinzler, K. W., & Vogelstein, B. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.05.068 · Cited by 34
Albella, B., Faircloth, G. T., Lázaro, L. L., Guzmán, C., Jimeno, J. M., & Bueren, J. A. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00245-3 · Cited by 31
Johnson, K. L., & Lawen, A. (1999) · Immunology and Cell Biology · doi:10.1046/j.1440-1711.1999.00821.x · Cited by 30
Mooberry, S. L., Taoka, C. R., & Busquets, L. (1996) · Cancer Letters · doi:10.1016/0304-3835(96)04342-x · Cited by 28
Yamashita, A., Norton, E. B., Kaplan, J. A., Niu, C., Loganzo, F., Hernandez, R., Beyer, C. F., Annable, T., Musto, S., Discafani, C. M., et al. (2004) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2004.08.024 · Cited by 26
Two Photoaffinity Analogues of the Tripeptide, Hemiasterlin, Exclusively Label α-Tubulin
Nunes, M., Kaplan, J. A., Wooters, J. L., Hari, M., Minnick, A. A., May, M. K., Shi, C., Musto, S., Beyer, C. F., Krishnamurthy, G., et al. (2005) · Biochemistry · doi:10.1021/bi0474766 · Cited by 25
Combination of trabectedin and irinotecan is highly effective in a human rhabdomyosarcoma xenograft
Riccardi, A., Meco, D., Ubezio, P., Mazzarella, G., Marabese, M., Faircloth, G. T., Jimeno, J. M., D’Incalci, M., & Riccardi, R. (2005) · Anti-Cancer Drugs · doi:10.1097/01.cad.0000172837.67766.6a · Cited by 25
Pfister, D. G., McCaffrey, J., Zahalsky, A. J., Schwartz, G. K., Lis, E., Gerald, W. L., Huvos, A. G., Shah, J. P., Kraus, D. H., Shaha, A. R., et al. (2002) · Investigational New Drugs · doi:10.1023/a:1014449309165 · Cited by 23
Composition and therapeutic utility of conotoxins from genus Conus. Patent status 1996 - 2000
Jones, R. M., Cartier, G. E., McIntosh, J. M., Bulaj, G. W., Farrar, V., & Olivera, B. M. (2001) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.11.4.603 · Cited by 20
Inhibition by Aplidine of the aggregation of the prion peptide PrP 106–126 into β-sheet fibrils
Pérez, M., Sadqi, M., Muñoz, V., & Ávila, J. (2003) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2003.08.003 · Cited by 20
Discodermolide: just another microtubule-stabilizing agent? No! A lesson in synergy.
Giannakakou, P., & Fojo, T. (2000) · PubMed · Cited by 20
Phase II Study of Trabectedin in Pretreated Patients with Advanced Colorectal Cancer
Paz-Ares, L. G., Rivera, F., Díaz‐Rubio, E., García, M., Casado, E., Cubedo, R., Grávalos, C., Alfaro, V., Gómez, J., Izquierdo, M. A., et al. (2007) · Clinical Colorectal Cancer · doi:10.3816/ccc.2007.n.018 · Cited by 13
Therapeutic impact of ET-743 (Yondelis; trabectidin), a new marine-derived compound, in sarcoma
Jimeno, J. M., Maki, R. G., Casali, P. G., Faircloth, G. T., Martı́nez, N., Nieto, A., Cañigueral, S., & Rinehart, K. (2003) · Current Opinion in Orthopedics · doi:10.1097/00001433-200312000-00011 · Cited by 11
Niu, C., Smith, D., Zask, A., Loganzo, F., Discafani, C. M., Beyer, C. F., Greenberger, L. M., & Ayral‐Kaloustian, S. (2004) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2004.05.077 · Cited by 6
Paterson, I., & Lyothier, I. (2005) · ChemInform · doi:10.1002/chin.200519227 · Cited by 4
Rinehart (2000) · doi:10.1002/(sici)1098-1128(200001)20:1<1::aid-med1>3.0.co;2-a
Cited by
Faulkner, D. J. (1990) · Natural Product Reports · doi:10.1039/np9900700269 · Cited by 4,866
Drug Discovery and Natural Products: End of an Era or an Endless Frontier?
Li, J. W.-H., & Vederas, J. C. (2009) · Science · doi:10.1126/science.1168243 · Cited by 2,052
Neurotoxic Alkaloids: Saxitoxin and Its Analogs
Wiese, M., D’Agostino, P. M., Mihali, T. K., Moffitt, M. C., & Neilan, B. A. (2010) · Marine Drugs · doi:10.3390/md8072185 · Cited by 769
Gerwick, W. H., & Moore, B. S. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2011.12.014 · Cited by 601
Martins, A., Vieira, H., Gaspar, H., & Santos, S. (2014) · Marine Drugs · doi:10.3390/md12021066 · Cited by 572
Metadata
- Authors
- Molinski, T. F., Dalisay, D. S., Lievens, S. L., & Saludes, J. P.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2008-12-19
- Volume
- 8
- Issue
- 1
- Pages
- 69-85
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1992084711
- Cited by
- 1,186
- References
- 197
- FWCI
- 5.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.